Millions of people have spat into test tubes for ancestry companies, but now there are questions being asked about what might happen to their DNA.
After a data breach, a sinking share price and mass board resignations, the chief executive of the Californian personal genomics firm 23andMe said she would consider selling the business. This means the DNA of its 15 million customers could also be up for grabs.
The valuation of 23andMe has "plummeted 99% from its $6 billion peak shortly after the company went public in 2021", said NPR. Its revenue for the first quarter of the 2025 fiscal year came to just $40 million, about 34% down on the same period the year before.
The business isn't bound by US health privacy laws like a GP practice, said The Atlantic, and its privacy policies "make clear that in the event of a merger or an acquisition, customer information is a saleable asset".
Although the company insists that it is committed to customer privacy, people who have submitted tests to discover ancestry lines or for healthcare research could "potentially leave their information vulnerable to threat actors", said The New York Times.
In a data breach last December hackers gained access to the personal information of nearly 7 million profiles by recycling old passwords that 23andMe customers had used on other sites that had been compromised.
So "if you ever used 23andMe", said PC Mag, you "might want to consider deleting your data while you still can".
|